Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) Return on Capital Employed (2020 - 2025)

Historic Return on Capital Employed for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to 0.22%.

  • Tarsus Pharmaceuticals' Return on Capital Employed rose 2300.0% to 0.22% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.22%, marking a year-over-year increase of 2300.0%. This contributed to the annual value of 0.5% for FY2024, which is 1800.0% up from last year.
  • According to the latest figures from Q3 2025, Tarsus Pharmaceuticals' Return on Capital Employed is 0.22%, which was up 2300.0% from 0.24% recorded in Q2 2025.
  • Tarsus Pharmaceuticals' Return on Capital Employed's 5-year high stood at 0.02% during Q2 2021, with a 5-year trough of 0.62% in Q4 2023.
  • For the 5-year period, Tarsus Pharmaceuticals' Return on Capital Employed averaged around 0.32%, with its median value being 0.29% (2022).
  • In the last 5 years, Tarsus Pharmaceuticals' Return on Capital Employed tumbled by -3300bps in 2023 and then soared by 2800bps in 2025.
  • Over the past 5 years, Tarsus Pharmaceuticals' Return on Capital Employed (Quarter) stood at 0.07% in 2021, then tumbled by -312bps to 0.29% in 2022, then crashed by -115bps to 0.62% in 2023, then skyrocketed by 35bps to 0.41% in 2024, then soared by 46bps to 0.22% in 2025.
  • Its Return on Capital Employed was 0.22% in Q3 2025, compared to 0.24% in Q2 2025 and 0.31% in Q1 2025.